الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 218 |  |  |
| | | from | 218 | | |
Abstract
This study included 100 patients with locally advanced rectal adenocarcinoma who presented and treated at Clinical Oncology and Nuclear Medicine Department, Tanta University Hospitals during the period from January 2018 to May 2020. The aim of the study is to evaluate patients‘ characteristics of locally advanced rectal cancer, compare treatment and toxicity outcomes between near total neoadjuvant therapy (short course radiotherapy, chemotherapy and total mesorectal excision) and neoadjuvant chemoradiotherapy (long course chemoradiotherapy and TME and adjuvant chemotherapy) and analyze factors which may affect disease response and survival with special emphasis on Glascow Prognostic scale. GPS was defined based on the presence of hypoalbuminemia (<35 g/L) and elevated CRP (>10 mg/L): if both were abnormal, the score was 2; if either was abnormal, the score was 1; if neither was abnormal, the score was 0. Locally advanced rectal cancer patients in this study were classified into two arms; arm1 :50 patients treated with short course radiotherapy followed 4 cycled FOLFOX4 and then TME and arm 2: 50 patients treated with conventional concurrent chemoradiation followed by TME then adjuvant chemotherapy. There were no significant differences for patients characteristics between the two groups as regard age, gender, clinical stage, grade, distance of tumor from anal verge, Kras/Nras and BRAF mutation pretreatment CEA level and pretreatment GPS.